

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/044,692
<i>(Use as many sheets as necessary)</i>				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	3	of	18	<i>Attorney Docket Number</i>	015389-002640US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Claims Appear
/PR/	1	US 2003-0096344 A1	05-22-2003	Cech et al.	
/PR/	2	US 2004-0242529 A1	12-02-2004	Cech et al.	
/PR/	3	US 2004-0247613 A1	12-09-2004	Cech et al.	
/PR/	4	US 2005-0013825 A1	01-20-2005	Cech et al.	
/PR/	5	US 4,554,101	11-19-1985	Hopp	
/PR/	6	US 5,001,225	03-19-1991	Taylor	
/PR/	7	US 5,075,227	12-24-1991	Hagen	
/PR/	8	US 5,639,613	06-17-1997	Shay et al.	
/PR/	9	US 5,853,719	12-29-1998	Nair et al.	
/PR/	10	US 5,919,656	07-06-1999	Harrington et al.	
/PR/	11	US 5,919,676	07-06-1999	Graham et al.	
/PR/	12	US 6,120,764	09-19-2000	Graham et al.	
/PR/	13	US 6,140,087	10-31-2000	Graham et al.	
/PR/	14	US 6,306,388 B1	10-23-2001	Nair et al.	
/PR/	15	US 6,387,701 B1	05-14-2002	Nair et al.	
/PR/	16	US 7,262,174 B2	08-28-2007	Jiang et al.	
/PR/	17	US 7,262,288 B1	08-28-2007	Cech et al.	
/PR/	18	US 7,285,639 B2	10-23-2007	Cech et al.	
/PR/	19	US Appl. No. 08/974,584		Cech et al.	
/PR/	20	US Appl. No. 09/721,477		Cech et al.	
/PR/	21	US 6,872,518 B2	03-29-2005	Zauderer	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country	Number ⁴		
	22	CA	2,194,393	A1 01-23-1990	Geron Corporation
	23	EP	0 700 915	A2 10-09-1997	Cold Spring Harbor Lab.

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	4	of	18	<i>Attorney Docket Number</i>	015389-002640US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T ²
		Country	Number ⁴	Kind Code ⁵ (if applicable)				
/PR/	24	WO	82/01461	A1	05-13-1982	Stanford University		<input type="checkbox"/>
/PR/	25	WO	97/38013	A1	10-16-1997	Geron Corporation		<input type="checkbox"/>
/PR/	26	WO	99/63945	A2	12-16-1999	Sloan-Kettering Institute		<input type="checkbox"/>
/PR/	27	WO	00/02581	A1	01-20-2000	Norsk Hydro AS		<input type="checkbox"/>
/PR/	28	WO	00/61766	A2	10-19-2000	Biomira, Inc.		<input type="checkbox"/>
/PR/	29	WO	00/73420	A2	12-07-2000	Whitehead Inst. et al.		<input type="checkbox"/>
/PR/	30	WO	01/60391	A1	08-23-2001	Regents of the Univ. of California		<input type="checkbox"/>
/PR/	31	WO	02/094213	A2	11-28-2002	Dow Coming Toray Silicone Co., Ltd.		<input type="checkbox"/>
/PR/	32	WO	03/038047	A2	05-08-2003	Baylor College of Medicine		<input type="checkbox"/>
/PR/	33	WO	96/01835	A1	01-25-1996	Geron Corporation		<input type="checkbox"/>
/PR/	34	WO	96/19580	A2	06-27-1996	Cold Spring Harbor Laboratory		<input type="checkbox"/>
/PR/	35	EP	1 093 381	B1	08-20-2003	GemVax AS		<input type="checkbox"/>
	36	NC	199951141		07-06-1999	Norsk Hydro ASA		<input type="checkbox"/>
	37	EP	0 007 370	B4	05-25-2005	Ephimone Inc.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/PR/	38	ALBERTS, B. et al., <i>Molecular Biology of the Cell</i> , Newton Press Inc., New York, p. 326, Fig. 7-43 (July 20, 1995).	<input type="checkbox"/>
/PR/	39	AUSUBEL, F. et al., <i>Current Protocols in Molecular Biology</i> , Vol. 1, Ch. 5, John Wiley & Sons, New York (1996).	<input type="checkbox"/>

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	5	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	40	BACHAND, F. & AUTEXIER, C., "Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions," <i>Mol. Cell. Biol.</i> 21:1888-97 (2001).			
/PR/	41	BANDYOPADHYAY, D. et al., "The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells," <i>Exp. Gerontol.</i> 36:1265-75 (2001).			
/PR/	42	BEASLEY, E. et al., "Statistical refinement of primer design parameters," <i>PCR Applications</i> , Innis et al., Eds., Academic Press, San Diego, pp. 55-71 (1999).			
/PR/	43	BELLONE, M. et al., "In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells," <i>Eur. J. Immunol.</i> 24:2691-8 (1994).			
/PR/	44	BELLONE, M. et al., "Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells," <i>J. Immunol.</i> 158:783-9 (1997).			
/PR/	45	BENEDICT, C. et al., "The long isoform of terminal deoxynucleotidyl transferase enters the nucleus and, rather than catalyzing nontemplated nucleotide addition, modulates the catalytic activity of the short isoform," <i>J. Exp. Med.</i> 193(1):89-99 (2001).			
	46	BERGER, S. & KIMMEL, A., "Preparation of cDNA and the generation of cDNA libraries: overview," <i>Meth. Enzymol.</i> 752:307-16 (1987).			
/PR/	47	BOCZKOWSKI, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo," <i>J. Exp. Med.</i> 184:465-72 (1996).			
/PR/	48	BOWIE, J. et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> 257:1306-10 (1990).			
/PR/	49	BRAMSON, J. et al. "The use of adenoviral vectors for gene therapy and gene transfer in vivo," <i>Curr. Opin. Biotechnol.</i> 6:590-5 (1995).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	6	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	50	BRYAN, T. et al., "A mutant of <i>Tetrahymena</i> telomerase reverse transcriptase with increased processivity," <i>J. Biol. Chem.</i> 275:24199-207 (2000).			
/PR/	51	BRYAN, T. et al., "Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase," <i>Molec. Cell</i> 6:493-99 (2000).			
/PR/	52	BURGESS, W. et al. "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>J. Cell Biol.</i> 111(5 Pt 1):2129-38 (1990).			
/PR/	53	COLE, S. et al., "The EBV-hybridoma technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , pp. 77-96, Alan R. Liss Inc., New York (1985).			
/PR/	54	COLGIN, L. et al., "The hTERT α splice variant is a dominant negative inhibitor of telomerase activity," <i>Neoplasia</i> 2(5):426-32 (2000).			
	55	CREIGHTON, T., <i>Proteins: Structures and Molecular Principles</i> , W.H. Freeman and Co, New York, Table of Contents (1983).			
/PR/	56	DAGARAG, M. et al. "Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1 specific T lymphocytes," <i>J. Virology</i> 77(5):3077-83 (2003).			
/PR/	57	DIEFFENBACH, C. & DVEKSLER, G. (Eds.), <i>PCR Primer, A Laboratory Manual</i> , CSHL Press, Woodbury, New York, Table of Contents (1995).			
/PR/	58	EMBL Database entry Greenberg et al., AF051911, XP002091313 (April 6, 1998).			
/PR/	59	EMBL Database entry Martin-Rivera et al., AF073311, XP002091314 (September 9, 1998).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	7	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	60	FARMERY, M. & BULLEID, N., "Major histocompatibility class I folding, assembly, and degradation: A paradigm for two-stage quality control in the endoplasmic reticulum," <i>Prog. Nucl. Acid Res. Mol. Biol.</i> 67:235-68 (2001).			
/PR/	61	FRANCO, S. et al., "Clonal variation in phenotype and life span of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT)," <i>Exp. Cell Res.</i> 268:14-25 (2001).			
/PR/	62	FRESHNEY, R., <i>Culture of Animal Cells, A Manual of Basic Technique</i> , Wiley-Liss, New York, pp. 3-4 (1983).			
/PR/	63	FRIEDMAN, K. et al., "Essential functions of amino-terminal domains in the yeast telomerase catalytic subunit revealed by selection for variable mutants," <i>Genes Dev.</i> 13(21):2863-74 (1999).			
/PR/	64	FROLKIS, M. et al., "Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors," <i>Cancer Gene Ther.</i> 10:239-49 (2003).			
/PR/	65	GRAY, J. et al., "Cloning and expression of genes for the Oxytricha telomere-binding protein specific subunit interactions in the telomeric complex," <i>Cell</i> 67:807-14 (1991).			
/PR/	66	GREENBERG, R. et al., "Expression of mouse telomerase reverse transcriptase during development, differentiation, and proliferation," <i>Oncogene</i> 16:1723-30 (1998).			
/PR/	67	GREENER, M., "Telomerase: The search for a universal cancer vaccine," <i>Mol. Med. Today</i> 6:257 (2000).			
/PR/	68	GREIDER, C., "Telomerase and senescence: The history, experiment, the future," <i>Curr. Biol.</i> 8(5):R178-81 (1998).			
/PR/	69	GURA, T., "Antisense has growing pains," <i>Science</i> 270:575-7 (1995).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	8	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	70	HAERING, C. et al., "Analysis of telomerase catalytic subunit mutants <i>in vivo</i> and <i>in vitro</i> in <i>Schizosaccharomyces pombe</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 97:6367-72 (2000).			
/PR/	71	HAHN, W. et al., "Inhibition of telomerase limits the growth of human cancer cells," <i>Nature Med.</i> 5:1164-70 (1999).			
/PR/	72	HARLEY, C., "Telomerase is not an oncogene," <i>Oncogene</i> 21:494-502 (2002).			
/PR/	73	HARRINGTON, L. et al., "Gel shift and UV cross-linking analysis of <i>Tetrahymena</i> telomerase," <i>J. Biol. Chem.</i> 270(15):8893-901 (1995).			
	74	HAUPT, K. et al., "The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy" <i>Biol Med Vol.</i> 227(4):227-237 (2002)			
/PR/	75	HE, T-C. et al., "A simplified system for generating recombinant adenoviruses," <i>Proc. Natl. Acad. Sci. USA</i> 95:2509-14 (1998).			
/PR/	76	HEISER, A. et al., "Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors," <i>Cancer Res.</i> 61:3388-93 (2001).			
/PR/	77	HEISER, A. et al., "Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA," <i>J. Immunol.</i> 166:2953-60 (2001).			
/PR/	78	HERBERT, J. et al., <i>The Dictionary of Immunology</i> , 3 rd Edition, Academic Press, London, pp. 58-59 (1985).			
/PR/	79	HERNÁNDEZ, J. et al., "Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> 99(19):12275-80 (2002).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	9	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	80	HIRASHIMA, M. "Ecalectin/galectin-9, a novel eosinophil chemoattractant: Its function and production," <i>Int. Arch. Allergy Immunol.</i> 122(Suppl. 1):6-9 (2000).			
/PR/	81	HUSTON, J. et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5879-83 (1988).			
/PR/	82	JIANG, D. et al., "Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca2+ release channel (ryanodine receptor)," <i>J. Biol. Chem.</i> 278(7):4763-9 (2003).			
/PR/	83	JIANG, X-R. et al., "Telomerase expression in human somatic cells does not include changes associated with a transformed phenotype," <i>Nat. Genet.</i> 21:111-4 (1999).			
/PR/	84	JOLLIFFE, L., "Humanized antibodies: enhancing therapeutic utility through antibody engineering," <i>Int. Rev. Immunol.</i> 10(2-3):241-50 (1993). (abstract only)			
/PR/	85	KIWAKI, K. et al., "Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter," <i>Hum. Gene Ther.</i> 7:821-30 (1996).			
/PR/	86	KIYONO, T. et al., "Both Rb/p16 ^{INK4a} inactivation and telomerase activity are required to immortalize human epithelial cells," <i>Nature</i> 396:84-8 (Nov. 1998).			
/PR/	87	KRAMS, M. et al., "Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas," <i>Am. J. Pathol.</i> 159(5):1925-32 (2001).			
/PR/	88	LAI, C. et al., "RNA binding domain of telomerase reverse transcriptase," <i>Mol. Cell. Biol.</i> 21:990-1000 (2001).			
/PR/	89	LANFRANCHI, G. et al., "Identification of 4370 expressed sequence tags from a 3'-end-specific cDNA library of human skeletal muscle by DNA sequencing and filter hybridization," <i>Genome Res.</i> 6:35-42 (1996).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/044,692
(Use as many sheets as necessary)				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	10	of	18	Attorney Docket Number	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/PR/	90	LANGFORD, L. et al., "Telomerase activity in ordinary meningiomas predicts poor outcome," <i>Hum. Pathol.</i> 28(4):416-20 (1997).			
/PR/	91	LAZAR, E. et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Mol. Cell. Biol.</i> 8:1247-52 (1988).			
/PR/	92	LEEM, S-H. et al., "The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions," <i>Oncogene</i> 21:769-77 (2002).			
/PR/	93	LI, H. et al., "Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells," <i>J. Biol. Chem.</i> 272:16729-32 (1997).			
/PR/	94	MARTIN-RIVERA, L. et al., "Expression of mouse telomerase catalytic subunit in embryos and adult tissues," <i>Proc. Natl. Acad. Sci. USA</i> 95:10471-6 (September 1998).			
/PR/	95	MEYERS, R., Ed., <i>Molecular Biology and Biotechnology, A Comprehensive Desk Reference</i> , Wiley-VCH, New York, p. 187 (1995).			
/PR/	96	Microbix Biosystems, Inc., AdMax™ adenovirus vector creation kits, 3 pages. http://www.microbix.com/products/PDFs/AdMaxVectorCreationKits.pdf			
/PR/	97	MORIN, G., "The implications of telomerase biochemistry for human disease," <i>Eur. J. Cancer</i> 33(5):750-60 (1997).			
/PR/	98	MURASAWA, S. et al., "Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells," <i>Circulation</i> 106:1133-9 (2002).			
/PR/	99	MURRAY, R. <i>McGraw Hill Yearbook of Science and Technology</i> , pp. 191-196, McGraw Hill, New York (1992).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	11	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	100	NAIR, D. et al., "Crystal structure of an antibody bound to an immunodominant peptide epitope: Novel features in peptide-antibody recognition," <i>J. Immunol.</i> 165(12):6949-55 (2000).			
/PR/	101	NAIR, S. et al., "Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines," <i>Eur. J. Immunol.</i> 27:589-97 (1997).			
/PR/	102	NAIR, S. et al., "Induction of cytotoxic t cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells," <i>Nature Med.</i> 6(8):1011-7 (2000).			
/PR/	103	NGO, J. et al., <i>The Protein Folding Problem and Tertiary Structure Predictor</i> , Mertz et al., Eds., Birkhauser, Boston, pp. 433, 492-5 (1994).			
/PR/	104	O'HARE, M. et al., "Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells," <i>Proc. Natl. Acad. Sci.</i> 98(2):646-51 (2001).			
/PR/	105	OHYASHIKI, J. et al., "Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells," <i>Brit. J. Cancer</i> 92:1942-7 (2005)			
/PR/	106	PEAR, W. et al., "Production of high-titer helper-free retroviruses by transient transfection," <i>Proc. Natl. Acad. Sci USA</i> 90:8392-6 (1993).			
/PR/	107	PEREZ, H. et al., "Human formyl peptide receptor ligand binding domain(s). Studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of receptor occupancy," <i>J. Biol. Chem.</i> 269(36):22485-7 (1994).			
/PR/	108	PING, L. et al., "Dramatic increase of telomerase activity during dendritic cell differentiation and maturation," <i>J. Leukoc. Biol.</i> 74:270-6 (2003).			
	109	<i>Protein Nucleic Acid and Enzyme</i> 42(9):1407-19 (July 1997). Japanese Language document No Translation			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	12	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	110	RAMIREZ, R. et al., "Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions," <i>Genes Dev.</i> 15:398-403 (2001).			
/PR/	111	RUDOLPH, K. et al., "Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery," <i>Science</i> 287:1253-8 (2000).			
/PR/	112	SADELAIN, M. et al., "Generation of a high-titer retroviral vector capable of expressing high levels of the human β -globin gene," <i>Proc. Natl. Acad. Sci. USA</i> 92:6728-32 (1995).			
/PR/	113	SAMBROOK, J. et al., Chapter 16: "Expression of Cloned Genes in Cultured Mammalian Cells," <i>Molecular Cloning, A Laboratory Manual</i> , CSHL Press, Plainview NY (1989).			
/PR/	114	SAMBROOK, J. et al., Chapter 17, "Expression of Cloned Genes in <i>Escherichia coli</i> ," <i>Molecular Cloning, A Laboratory Manual</i> , CSHL Press, Plainview, NY (1989).			
/PR/	115	SAMBROOK, J. et al., Chapter 8: "Construction and Analysis of cDNA Libraries," <i>Molecular Cloning, A Laboratory Manual</i> , CSHL Press, Plainview, NY (1989).			
/PR/	116	SKOLNICK, J. & FETROW, J., "From genes to protein structure and function: Novel applications of computational approaches in the genomic area," <i>Tibtech</i> 18:34-9 (2000).			
/PR/	117	SOLHEIM, J., "Class I MHC molecules: Assembly and antigen presentation," <i>Immunol. Rev.</i> 172:11-19 (1999).			
/PR/	118	Stratagene Catalog, p. 39 (1988).			
/PR/	119	SU, Z. et al., "Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells," <i>Cancer Res.</i> 63:2127-33 (2003).			

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/044,692
(Use as many sheets as necessary)				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	13	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	120	TANI, K. et al., "Transduction of LacZ gene into leukemia cells using viral vectors of retrovirus and adenovirus," <i>Leukemia</i> 9(Suppl. 1):S64-5 (1995).			
	121	The Adjustment Foundation of Science and Technology Promotion News, Vol. 160 (1997 Jul 11) p-0-6.			
	122	Tissue Culture, vol. 20(1) (1997 Jan) p. 1-11 Japanese language document No Translation			
/PR/	123	VAZIRI, H. & BENCHIMOL, S., "Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span," <i>Curr. Biol.</i> 8(5):279-82 (1998).			
/PR/	124	VERMA, R. & BABU, S., <i>Human Chromosomes: A Manual of Basic Techniques</i> , Pergamon Press, New York, Table of Contents (1988).			
/PR/	125	XIA, J. et al., "Identification of functionally important domains in the N-terminal region of telomerase reverse transcriptase," <i>Mol. Cell. Biol.</i> 20:5196-207 (2000).			
/PR/	126	YI, X. et al., "Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells," <i>Nucl. Acids Res.</i> 23:4818-25 (2001).			
	127	OKADA, Y. & IKEDA, J. (Eds.), "Expression of information and control in higher plant," <i>Development of Molecular Biology</i> 13, Japanese Molecular Biology Association edition, Maruzen Corp. pp. 262-263 (Feb 10, 1990).			
	128	ZAKHAROVA, O. et al., "Structural constraints in the HIV-1 reverse transcriptase-primer/template complex for the initiation of DNA synthesis from primer tRNA ^{Gln} ," <i>Biochem.</i> 37:13343-6 (1998).			
/PR/	129	Accession No. AA281296, GenBank (Apr 2/97).			<input type="checkbox"/>

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	14	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/PR/	130	KEITH et al, Telomerase-Directed Molecular Therapeutics, Exp Rev Mol Med (Apr 22/02).	<input type="checkbox"/>	T ²
/PR/	131	LEMOINE et al, Mutant Oncogenes, Targets for Therapy, Chapman & Hall Med (1993).	<input type="checkbox"/>	
/PR/	132	Prendergast's Applications, Judgment of UK Patents Court, Reports of Patent Cases, p446 (Jul 07/99).	<input type="checkbox"/>	
/PR/	133	Prendergast's Applications, Judgment of UK Patents Court, Reports of Patent Cases, p446 (Jul 07/99).	<input type="checkbox"/>	
/PR/	134	GANDHI et al, Interaction of Recombinant <i>Tetrahymena</i> Telomerase Proteins p80 and p95 with Telomerase RNA and Telomeric DNA Substrates, Genes & Dev 12:721 (1998).	<input type="checkbox"/>	
/PR/	135	BROWN et al, Vaccine Design – Requirements for the Induction of Immunity, Mol Med Sci Series, p25 (1993).	<input type="checkbox"/>	
/PR/	136	STITES et al, Clinical Laboratory Methods for Detection of Cellular Immune Function, Basic & Clin Immunol 20:353 (1984).	<input type="checkbox"/>	
/PR/	137	ROITT et al, Hypersensitivity – Type I, Immunol (1996) 22.1. and Roitt et al, Hypersensitivity – Type IV, Immunol (1996) 25.1.	<input type="checkbox"/>	
/PR/	138	PARKER et al, Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains, J Immunol 152(1):163 (1994).	<input type="checkbox"/>	
/PR/	139	Results of search for HLA-A2.1 sequences motifs in hTRT, BIMAS web (Dec 19/00).	<input type="checkbox"/>	

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	15	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/PR/	140	DAVENPORT et al, An Empirical Method for the Prediction of T-Cell Epitopes, Immunogen 42:392 (1995).			<input type="checkbox"/>
/PR/	141	MEISTER et al, Two Novel T Cell Epitope Prediction Algorithms Based on MHC-Binding Motifs; Comparison of Predicted and Published Epitopes from <i>Mycobacterium Tuberculosis</i> and HIV Protein Sequences, Vaccine 13(6):581 (1995).			<input type="checkbox"/>
/PR/	142	HAMMER et al, HLA Class II Peptide Binding Specificity and Autoimmunity, Advances in Immunol 66:67 (1997).			<input type="checkbox"/>
/PR/	143	GAUDERNACK et al, Clinical Trials of a Peptide Based Vaccine Targeting Telomerase, Abstract P11, British Assn Cancer Res Conf (Oct 12/04).			<input type="checkbox"/>
/PR/	144	Declaration of Prof. David Sherratt, w/ CV, Apr 13/06.			<input type="checkbox"/>
/PR/	145	SCARDINO et al, HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy, J Immunol 168:5900 (2002).			<input type="checkbox"/>
/PR/	146	Declaration of Dr. Scott L Weinrich, Dec 23/99.			<input type="checkbox"/>
/PR/	147	SCHROERS et al, Human Telomerase Reverse Transcriptase-Specific T-Helper Responses Induced by Promiscuous Major Histocompatibility Complex Class II-Restricted Epitopes, Clin Cancer Res 9:4743 (Oct 15/03).			<input type="checkbox"/>
/PR/	148	Declaration of Dr. Calvin Harley, w/ CV, Apr 12/06.			<input type="checkbox"/>
/PR/	149	Results of search for HLA-A2.1 sequences motifs in hTRT, BIMAS web (Jul 5/04).			<input type="checkbox"/>

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan MNM
Sheet	16	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	150	BRYAN et al, Telomerase Reverse Transcriptase Genes Identified in <i>Tetrahymena Thermophila</i> and <i>Oxytricha Trifallax</i> , PNAS 95:8479 (Jul 98).			<input type="checkbox"/>
/PR/	151	Results of search for HLA-A2.1 sequences motifs in hTRT, BIMAS web (Jul 5/04).			<input type="checkbox"/>
/PR/	152	Declaration of Prof. David Wraith, w/ CV, Exhibits, Apr 9/06. Magee et al, Exhibit 1 – Two Classes of Fatty Acid Acylated Proteins Exist in Eukaryotic Cells, EMBO J 4(5):1137 (1985). Klockmann et al, Exhibit 2 – Evidence for Transmembrane Orientation of Acylated Simian Virus 40 Large T Antigen, J Virology 56(2):541 (Nov 85). Bockenstedt et al, Exhibit 3 – Self-Peptides in the Initiation of Lupus Autoreactivity, J Immunology 154:3516 (1995).			<input type="checkbox"/>
PR/	153	Results of search for HLA-A2.1 sequences motifs in hTRT, BIMAS web (Jul 5/04).			<input type="checkbox"/>
/PR/	154	Declaration of Anish Majumdar Ph.D., w/ CV, Exhibits, Feb 8/06.			<input type="checkbox"/>
/PR/	155	Results of search for HLA-A2.1 sequences motifs in hTRT, BIMAS web (Jul 5/04).			<input type="checkbox"/>
/PR/	156	RUPPERT et al, Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules, Cell 74:929 (Sep 10/93).			<input type="checkbox"/>
/PR/	157	Results of search for HLA-A2.1 sequences motifs in hTRT, BIMAS web (Jul 5/04).			<input type="checkbox"/>
/PR/	158	CELIS et al, Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five common HLA-A Alleles, Mol Immunol 31(18):1423 (1994).			<input type="checkbox"/>

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	17	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	159	<u>Sequence comparison of the sequence of D1, EMBL</u>				<input type="checkbox"/>
/PR/	160	CELIS et al, Epitope Selection and Development of Peptide Based Vaccines to Treat Cancer, <u>Cancer Biol 6:329 (1995).</u>				<input type="checkbox"/>
/PR/	161	SUNG et al, The Pleiotropy of Telomerase Against Cell Death, <u>Mol Cells 19(3):303 (Jun 05).</u>				<input type="checkbox"/>
/PR/	162	APPELLA et al, Synthetic Antigenic Peptides as a New Strategy for Immunotherapy of Cancer, <u>PNAS 1:177 (1995).</u>				<input type="checkbox"/>
/PR/	163	PARMIANI et al, Cancer Immunotherapy with Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? <u>J Natl Cancer Inst 94(11):805 (Jun 5/02).</u>				<input type="checkbox"/>
	164	<u>Printout showing electronic Parker Algorithm, BiMAS web (Feb 15/05).</u>				<input type="checkbox"/>
/PR/	165	Cancer Vaccination review, <u>Biotext. (2006)</u>				<input type="checkbox"/>
	166	<u>Printout of Algorithm applied to HTRT sequence, BiMAS web (Dec 14/04).</u>				<input type="checkbox"/>
/PR/	167	ZAUDERER, (U Rochester), Methods for Selecting Polynucleotides Encoding T Cell Epitopes, <u>USP 6,872,518 (Mar 29/05).</u>				<input type="checkbox"/>
/PR/	168	RAJAGOPAL et al, Diversity and Overlap in the Mechanisms of Processing Protein Antigens for Presentation to T Cells, <u>Indian J Med Res 120:75 (Aug 04).</u>				<input type="checkbox"/>

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/044,692
				<i>Filing Date</i>	January 11, 2002
				<i>First Named Inventor</i>	
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	Ungar, Susan NMN
Sheet	18	of	18	<i>Attorney Docket Number</i>	015389-002640US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/PR/	169	Declaration of Dr. Alessandro Sette, w/ CV, Apr 11/06.			<input type="checkbox"/>
/PR/	170	VONDERHEIDE et al, The Telomerase Catalytic Subunit is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes, Immunity 10:673 (Jun 89).			<input type="checkbox"/>
/PR/	171	MINEV et al, Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase in Humans, PNAS 97(9):4796 (Apr 25/00).			<input type="checkbox"/>
/PR/	172	VONDERHEIDE, Telomerase as a Universal Tumor-Associated Antigen for Cancer Immunotherapy, Oncogene 21:674 (2002).			<input type="checkbox"/>
/PR/	173	VONDERHEIDE et al, Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes, Clin Cancer Res 10:828 (Feb 1/04).			<input type="checkbox"/>
/PR/	174	AYYOUB et al, Lack of Tumor Recognition by hTERT Peptide 540-548-Specific CD8 ⁺ T Cells from Melanoma Patients Reveals Inefficient Antigen Processing, Eur J Immunol 31:2642 (2001).			<input type="checkbox"/>
/PR/	175	GROSS, et al, High Vaccination Efficiency of Low-Affinity Epitopes in Antitumor Immunotherapy, J Clin Invest 113(3):425 (Feb 04).			<input type="checkbox"/>
/PR/	176	interlocutory decision in Opposition Proceeding (Articles 102(3) and 106(3) EPC for EP Application 97 307 757.1-2406 / 841397 / 01			<input type="checkbox"/>

Examiner Signature	/Peter Reddig/	Date Considered	05/28/2008
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.